

FICC Tail Wags The Dog

The Great Financial Moderation And Triggers For FICC

- **FICC Tail** — Wholesale bank valuations are largely being driven by their FICC dependence. Markets remain deeply sceptical of the FICC business model — revenue outlook, profitability, market positioning, as well as litigation risks.
- **FICC Revenue Pool Fades** — In 2013, the global FICC revenue pool declined by 13% to US\$107bn. Recently, various management teams have indicated a weak start to FICC, with double-digit declines. This clearly raises risks to our broadly stable 2014 FICC revenue pool assumptions; in [Tough Start to 2014, Earnings Risk?](#) (21-Feb-14) we estimated up to c7-8% EPS hit for a 10% FICC decline.
- **More Cyclical Than Structural** — Although scant consolation near-term, we argue recent FICC weakness has been more *cyclical* than structural. Several US banks indicated no material impact from derivatives clearing and final Volcker rules. As highlighted in [The Regulatory "Tunnel" Getting Longer, but a Bit Brighter](#) (04-Mar-13), we estimated rising headwinds of c6-7% over 2014-15 from shift to SEF trading followed by un-cleared derivatives rules (from 2015). Thus, we estimate that some two-thirds of FICC regulatory impact is already 'baked-in'.
- **The Great Financial Moderation; Trend is Macro's Friend** — The low rates, low volatility environment continues to weigh significantly on Global Macro (Rates & FX) — c45-50% of FICC revenue pool — partly offset by a more resilient performance in Credit. This impacts Barclays and Deutsche Bank more than Credit Suisse given the latter's bias to Credit, EM and Securitisation. FICC would benefit from trend with moderate volatility — likely into an environment of diverging monetary paths in 2015 taking the 'normalised' FICC revenue closer to US\$120bn vs. reported cUS\$100bn.
- **Industry Returns Match Cost of Capital** — In 2013, the industry delivered a c12.5% RoE, modestly up from c12% in 2012 (based on 10% of B3 RWAs). A harsher view including Non-Core, which is being progressively wound-down, suggests c10% underlying sector RoE, with FICC-biased franchises lagging.
- **Non-Core Wind-Down to Up Returns** — Decommissioning non-core operations, would serve to improve European sector returns by c2-4ppt to 12-14% & taking CS, Deutsche Bank and UBS materially higher compared to implied valuations significantly below book. However, execution is key. In the absence of market & market share recovery, BNP Paribas and Barclays may require further restructuring.
- **Equities Bias for Now, FICC into 2015** — We continue to prefer more equity-biased franchises and recently added SocGen to our Focus list while UBS also remains well-placed. With Equities comparably-sized to FICC, we think CS remains best-positioned to achieve 'escape velocity' from the FICC trap. Swiss banks should also benefit from improving net margins in their Wealth Management franchises with additional gearing to higher USD interest rate curves. By contrast, the fortunes of Barclays and Deutsche Bank are tied to rising volatility and trends in the Global Macro space; we see material upside, albeit more likely at the turn of 2015.

Kinner Lakhani

+44-20-7986-4258
kinner.lakhani@citi.com

Nicholas Herman

+44-20-7986-4203
nicholas.herman@citi.com

Andrew Coombs
andrew.coombs@citi.com

European Banks Team

Rahul Bajaj

Ronit Ghose

Azzurra Guelfi

Stefan Nedialkov

Simon Nellis

Florent Nitu

Vikas Sharma

Yafei Tian

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Certain products (not inconsistent with the author's published research) are available only on Citi's portals.

The Great Financial Moderation


Wholesale banks exhibit strong correlation in valuation with FICC dependence

More than ever, wholesale bank valuations are being driven by concerns over the FICC business. After all, forward PE multiples demonstrate strong correlation with Group revenue dependence on the FICC business (c70%), as shown in Figure 1. We attribute this to a combination of *structural* and *cyclical* concerns on the outlook for both profitability and growth of the FICC business:

- **Structural issues** include the impact of regulation, notably Basel 3, OTC derivatives reform and Volcker (refer to [Sizing Up "The Elephant in the Room"](#), 01-Jun-12).
- **Cyclical concerns** with the global FICC revenue pool declining by c13% in 2013 and recent management guidance of a weak start to 2014, discussed next, in what we consider the Great Financial Moderation.

The combination of Fed QE and lack of trend has served to significantly depress volatility and customer activity in the Global Macro franchises, namely Rates & FX, which represent c45-50% of FICC revenue.


Figure 1. Wholesale Bank Valuations are Correlated with FICC Dependence



Source: Citi Research

Note: 2015E P/E multiples; 2015E FICC revenues as a % of Group revenue

Figure 2. FICC Revenue Breakdown, 2013



Source: Coalition, Citi Research

Note: EM revenues split 45% FX, 30% Rates, 15% Credit, 10% Commodities


Global Macro Impacted By Low Volatility

FX and Rates volumes significantly impacted by low volatility

Both FX and Rates demonstrate a significant correlation with volatility (see Figure 3 and Figure 4), which has continued to decline as steady policy action and geopolitical uncertainty have weighed.

Although Credit has remained somewhat more resilient — supported by tightening spreads — this remains a smaller part of the overall FICC revenue pool at c25-30%. In the near-term, Securitisation may have seen its peak as the opportunity around legacy structured credit product declines while the private securitisation markets have yet to fully take-off.


Figure 3. Rates Revenues Highly Correlated with Volatility¹



Source: Coalition, Bloomberg, Citi Research

Note: 1. Based on MOVE index; 2. $R^2 = 65\%$

Figure 4. Forex Revenues Correlated with FX Volatility¹



Source: Coalition, Bloomberg, Citi Research

Note: 1. Based on CVIX index; 2. $R^2 = 47\%$

The Regulatory Tunnel is Long, But Manageable

Two-thirds of FICC regulatory impact 'baked-in, although further 6-7% 'hit' to come

In [The Regulatory "Tunnel" Getting Longer, but a Bit Brighter](#) (04-Mar-13), we estimated a cumulative impact of c6-7% based on rising headwinds over 2014-15 from the shift to SEF (swap execution facilities) trading followed by un-cleared derivatives rules (from 2015). This is consistent with JPMorgan's recent guidance of a c6% impact on FICC sales & trading revenues from upcoming derivatives regulation (see Figure 5 and Figure 6).


Most banks have largely adapted to Basel 3 requirements, while the impact from derivatives clearing & post-trade transparency has been relatively limited. US banks also indicated a relatively limited impact from the final Volcker rules, as noted in [Handover Continues; Regulation Eases](#) (29-Jan-14).

Figure 5. Global Derivatives Regulatory Timeline

Management Commentary		Expected Timing by Region		
Regulation	Comment	US	Europe	Asia
Post-trade transparency	Live in US for CFTC Products Impact limited to date but difficult to isolate and quantify	In Progress	2016	2016+
Clearing	Live in US for CFTC Products, with no significant impact Credit sensitive corporates exempt	In Progress	2014+	In progress - Japan only
SEF trading	Went live February 2014 in US for Rates – too early to observe impact	2014	End 2016	2016+
Initial margin on un-cleared swaps	Additional funding cost for initial margin expected to be significant, but phase-in over a long period	2015+	2015+	2015+

Source: JPMorgan Chase & Co

Figure 6. JPM – CIB Markets business: Potential impact from market structure regulations



Source: JPMorgan Chase; Note: 1. Credit includes Securitised Products


National subsidiarisation remains a key risk to efficiently running one of the few globalised parts of the financial services industry. Most notably, the recently-announced US FBO rules allayed worst fears around timing with application of leverage requirements not until Jan 1, 2018 and clarification on funding: “*The foreign proposal would not have imposed a cap on cross-border intragroup flows*”. This removes another layer of regulatory uncertainty and should afford the likes of Barclays and Deutsche Bank the time to further optimise their US operations.

What are the Catalysts for FICC?

We estimate a normalised FICC revenue pool of c.\$120bn, consistent with our previous estimates


We continue to forecast a 'normalised' FICC revenue pool of c.US\$120bn, or almost 20% above 2013 levels. This remains consistent with our view from [Sizing Up "The Elephant in the Room"](#), 01-Jun-12, except that we estimate some two-thirds of regulatory headwinds are behind us. Cyclical factors continue to weigh, which we expect to rebound, over time, offset by the further regulatory impact of OTC derivatives reform.

Figure 7. Citi Estimates Of Adjusted Global FICC Revenue Pool As At 01-Jun-12...



Source: Citi Research Estimates: [Sizing Up "The Elephant in the Room"](#), 01-Jun-12

Figure 8. ...We Still View Adjusted Global FICC Revenue Pool At \$121bn



Source: Company Reports, Citi Research Estimates

Trend is Macro's Friend

Trend is your friend in Global Macro


"Trending markets with moderate levels of volatility generally positive for trading volume" – JPM Investor Day (25-Feb-14).

Global Macro products tend to be price agnostic and supported by moderate volatility, i.e. 'trend is your friend'. However, the endgame of Fed tapering, which implies a substitution effect in the private markets as well as a resurgence of better economic data, could eventually rekindle Global Macro activity.

From a 1% growth rate, our economists have pencilled in 3.5% GDP growth in 2Q14 (>3% to 2016E) and an aggressive +300k on payrolls. In other words, we are looking for a divergence in central bank actions across the major economic blocs. The contra to such a trend would be, of course, if such a move were accompanied by an extreme increase in volatility, i.e. a shock increase in the UST yield curve.

The past 15 months have seen a significant increase in the US yield curve, with the long end of the curve rising by c.1%. This includes YTD performance that has seen a rise in the short end of the curve (10bps for 2-4 year).

Figure 9. US Yield Curve Has Fallen YTD, Although Recent Fed Comments Have Boosted The Short End Of The Curve



Source: Bloomberg, Citi Research


By contrast, the Credit and Securitisation business tends to be more directional, i.e. supported by tightening credit spreads. Although arguably the best is behind us, we see the 'search for yield' as continuing to be a supportive driver, for now.

Focus on Returns

Including Non-Core, IB industry generated 10% RoE with FICC-biased players lagging

On a headline basis (excl. non-core operations), the global IB industry generated a 2013 RoE of 12.4%, improving from 11.4% in 2012. European banks delivered returns of almost 14%, significantly ahead of US banks (c10%). A harsher view that accounts for the non-core operations of Barclays, CS, Deutsche Bank and UBS would reduce both the European and Global IB returns to c.10%.

Figure 10. IB RoEs By Geographic Region – Including & Excluding Non-Core (2013)




Source: Company Research

Not All Banks Are Equal


On a headline basis, European IB divisions reported 2013 B3 RoE of 9-30%, led by UBS (see Figure 11). Adjusting for underlying non-core earnings 'drag', returns ranged from 7-16% led by the more Equities-biased SocGen, CS and UBS franchises. By contrast, the more FICC-biased businesses of Barclays, Deutsche Bank and BNP Paribas lagged with returns of c7-9%.

Figure 11. Comparative IB RoEs – Incl. & Excl. Non-Core (2013)



Source: Company Reports, Citi Research Estimates
Note: Non-core excludes restructuring and litigation charges

Figure 12. Comparative EQ vs FICC Revenue Mix (2013)




Source: Company Reports, Citi Research Estimate
Note: Based on 2013 underlying EQ revenues as a % of underlying FICC revenues.

Kicking The Tyres on FICC

A further 10% FICC decline would reduce IB returns from 10% to 9%

Given continued weakness, we stress-test returns for a potential 10% decline in the FICC revenue pool. At the sector level, this would reduce returns from 10% to 9%, assuming a relatively limited comp-to-revenue ratio offset of 10%. Not surprisingly, banks with a greater bias to FICC are more impacted, with Barclays and Deutsche Bank returns declining to c6%. While CS' RoE declines the most (>2%), its bias to Credit, EM and Securitisation could suggest greater FICC revenue resilience.


Figure 13. European IB Sector RoE – 2013 Vs. Stressed (10% FICC Decline)



Source: Company Reports, Citi Research Estimates

Note: 'Stressed' scenario involves a 10% decline in FICC revenues, partially offset by a decline in compensation that is equivalent to one-tenth of the revenue loss. Non-core excludes restructuring and litigation charges

Figure 14. European IBs RoE – 2013 Vs. Stressed (10% FICC Decline)




Non-Core Deleveraging To Materially Raise Returns

Decommissioning Non-Core would raise sector returns by 2-4ppt

Although near-term returns remain depressed, de-commissioning the non-core divisions should serve to materially enhance sector returns to c12-14%. The most notable return improvement should come from UBS (to 26%), followed by Deutsche Bank (to 19%) and CS (to 17%). By contrast, in the absence of market tailwinds or regaining lost FICC market share, the likes of BNP Paribas and Barclays may need to take further action to improve returns (from c9%).


Figure 15. European IB Sector RoE – 2013 Vs. Non-Core Wind Down



Source: Company Reports, Citi Research Estimates

Note: 1. Scenario 1 assumes 67% reduction of 2013 non-core operating drag; Scenario 2 assumes 25% of residual non-core costs are incorporated into core expense base. Non-core excludes restructuring and litigation charges

Figure 16. Comparative IB Returns – Impact of Non-Core Wind-down




We assume two separate scenarios for the operational drag from the non-core division:

- **Reduction in Non-Core Losses (Scenario 1):** We assume a two-thirds reduction in the 2013 operating drag, excluding litigation and restructuring costs;
- **Reduction in Non-Core Expenses (Scenario 2):** We assume that there are residual 'stranded' costs equating to c25% of the 2013 non-core cost base, excluding litigation and restructuring costs.

Productivity on Assets More Equal Than Franchise Efficiency

Given that investment banking is amongst the most globalised of segments in the financial services industry, perhaps it is no surprise that the productivity or revenue on assets are typically in a tight range of c2-2.5% (JPM also includes Investor Services). Differences in profitability can be attributed more to efficiency — both cost (scale) and capital (product mix).

Figure 17. Comparative IB Productivity: Revenue on Assets (2012-2013)



Source: Company Reports, Citi Research
Note: Based on US GAAP or equivalent assets

Based on US GAAP assets (not available for all European banks), CS and DBK (strategic IB units) have broadly peer group average revenue-on-assets and margins, with higher returns being supported by higher leverage/lower risk-weights. Thus, on a peer group average or 'normalised' basis of leverage, both CS and DBK strategic units show industry average returns of 13-14%.

We expect the Basel agenda in 2014 to increasingly focus on risk-weighting. Although this could potentially drive up risk-weightings of European franchises — via use of more onerous model choices (e.g. VaR input horizon, migration/correlation assumptions) — we believe that differences in business models, as well as the 'super-equivalent' approach of certain regulators (e.g. US), are more significant drivers of differences in risk-weighting. Refer to [Wholesale Banks & The RWA Debate](#), 31-Jan-13.

Profitability and Valuation of Investment Bank Divisions


Figure 18. European IB Division DuPont Analysis – RoA and RoE breakdown (2012-2013)

	Revenue on Assets (%) (1)		Post-tax Margin (%) (2)		RoA (%) (1) * (2) = (3)		Assets / 10% RWA (4)	(5)	RoE (%) = (3) * (4)	RoE (%) = (3) * (5)
	2012	2013	2012	2013	2012	2013	2013	'Norm'	2013	'Norm'
JPM CIB	3.2%	3.0%	26.6%	28.3%	0.84%	0.85%	19	25	16%	21%
CS IB SU	2.3%	2.6%	21.5%	22.0%	0.50%	0.57%	36	25	20%	14%
MS ISG	2.4%	2.4%	14.5%	14.0%	0.35%	0.34%	18	25	6%	9%
DBK CB&S	2.3%	2.4%	21.1%	21.6%	0.48%	0.51%	37	25	19%	13%
GS ICS	2.2%	2.0%	22.1%	17.9%	0.49%	0.36%	17	25	6%	9%
Average	2.4%	2.5%	22.4%	21.1%	0.55%	0.54%	25	25	11%	11%

Source: Company Reports, Citi Research

Note: 1) Based on US GAAP or equivalent assets; 2) 'Norm' RoE based on sector simple average leverage ratio(assets / equity)

Figure 19. European IBs – 2013 RoA vs. 'Normalised' RoE



Source: Company Reports, Citi Research Estimates

Figure 20. Implied Valuations of European IB Divisions

Figures in USD (bn)	Mkt Cap	Non-IB Valuation	Other Capital (+/-)	Implied IB Valuation	10% IB B3 RWA	Implied IB P/BV
Barclays	62.0	52.6	12.2	(2.8)	30.8	(0.1x)
Credit Suisse	54.6	41.1	0.5	12.9	15.5	0.8x
Deutsche Bank	45.3	45.9	(9.0)	8.4	21.2	0.4x
UBS	76.4	71.5	2.6	2.3	6.9	0.3x
Total	238.2	211.1	6.3	20.8	74.6	0.3x

Source: Citi Research

Note: 1. Non-IB valuation based on Citi sum-of-the-parts valuation analysis of non-investment bank divisions; 2. Other capital refers to a) NPV of dividends to 2016 for Barclays; b) capital surplus vs. a 11.5% and 13.0% CET1 capital ratio in 2014 for CS and UBS respectively; and c) capital deficit vs. 4.0% leverage ratio in 2014 for Deutsche Bank

To The Winners, The Spoils

Radical FICCx

Since pre-crisis levels, top 5 FICC markets shares have increased by 7ppt and by 3ppt in EQ. This trend of consolidation — which was led by UBS — has been driven by the pressure on returns from both regulation (Basel 3, OTC derivatives reform, Volcker) as well as cyclical pressures. We expect these trends to continue, notably with RBS drawing back to its 'roots' in the UK.

Winners & Losers

Based on JPMorgan analysis of leadership positions — disclosed at its 2013-14 Investor Days:

- **US banks** have generally gained market share over their US peers, with the notable exception of Morgan Stanley
- **Swiss banks** have lost share as they have 'narrowed' their focus in the FICC space
- **Deutsche Bank** has held its own with market share losses driven more by geographic mix (ie greater bias to Europe & Asia) than intrinsic. By contrast, Barclays may have lost some positioning in areas such as FX and securitisation, partly offset by stronger credit.

Figure 21. Wholesale Banks – Investment Banking Product Strength Matrix (2013)

Total Leadership Positions, 2013 And Change On 2012 Positions	JPM	GS	BAC	MS	C	DBK	CS	UBS	BARC	BNPP
	15	8	5	5	5	4	2	2	1	0
Origination & Advisory										
Bond Underwriting				↑	↓	↑	↓		↓	n/a
Loan Syndication	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
ECM		↑	↓					↓		n/a
M&A			↓		↑	↓	↓			n/a
USD Clearing	↑		↑		↑	↑				
FICC										
G10 Rates					↓	↑				n/a
G10 Credit		↑		↓	↑	↓	↓		↑	n/a
G10 Foreign Exchange		↑			↑				↓	n/a
Securitisation		↓			↑	↑				n/a
Emerging Markets							↓			n/a
Commodities			↓	↑		↓		↓		n/a
Municipal Finance	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Equities										
Cash Equities										n/a
Derivatives & Convertibles			↑	↓	↓		↓	↑	↓	n/a
Prime Brokerage	↑						↓			n/a
Futures & Options				↓	↓		↓			n/a
Key										
Top 3										
2nd Tier										
3rd Tier										

Source: Company Reports (JP Morgan 2014 Investor Day, CIB Presentation), Citi Research Estimates

Note: 1. Arrows indicate change in position on 2012. 2. BNPP is a new entry so no comparison on 2012. 3. Loan syndication and Municipal Finance are new disclosures so no comparison on 2012.

Figure 22. Wholesale Banks – Estimated Change In Investment Banking Leadership Positions (2012-2013)

2012					2013				YoY Δ (%)
	Top 3	2nd Tier	3rd Tier	Weighted	Top 3	2nd Tier	3rd Tier	Weighted	
JP Morgan	28%	4%	-%	18.1%	JP Morgan	31%	2%	-%	1.2%
Goldman Sachs	18%	10%	3%	14.2%	Goldman Sachs	18%	11%	3%	0.2%
Citi	8%	12%	14%	9.7%	Citi	9%	11%	10%	(0.0%)
Bank of America	10%	14%	7%	11.1%	Bank of America	11%	18%	3%	1.2%
Deutsche Bank	10%	14%	7%	11.1%	Deutsche Bank	9%	18%	5%	0.0%
Barclays	5%	14%	14%	8.7%	Barclays	2%	18%	10%	(1.1%)
Morgan Stanley	10%	8%	17%	10.3%	Morgan Stanley	11%	4%	13%	(1.0%)
Credit Suisse	8%	12%	14%	9.7%	Credit Suisse	4%	7%	17%	(3.3%)
UBS	3%	10%	24%	7.0%	UBS	4%	4%	18%	(1.2%)
Nomura	-%	-%	-%	-%	Nomura	-%	-%	-%	-%
BNP Paribas	-%	-%	-%	-%	BNP Paribas	-%	7%	20%	-%
Total	100%	100%	100%	100.0%	Total	100%	100%	100%	-%

Source: Company Reports (JP Morgan 2014 Investor Day, CIB Presentation), Citi Research Estimates

Note: assumes weightings that Top 3 is twice 2nd Tier, which in turn is three times 3rd Tier

Competitive Advantages of the Future

Looking ahead, we believe that the new sources of competitive advantage will prevail (discussed in [Sizing Up “The Elephant in the Room”](#), 01-Jun-12):

- **Electronic execution & technology leadership**, especially in the context of shifting to SEF trading;
- **Clearing & collateral management** as an opportunity for banks to deepen and consolidate client relationships and increase trading/execution share, similar to prime brokerage;
- **Franchise presence — depth & mix over breadth**: Given the increasing balance sheet constraints, fewer banks will be able to deploy the breadth and depth of franchise footprint, compared to pre-crisis levels. As witnessed at UBS, franchise depth and business mix considerations will increasingly gain, at the expense of breadth;
- **Emerging markets strength**: Although EM faces tough cyclical headwinds, the medium- to long-term opportunity remains significant on the back of significantly lower financial penetration; and
- **Corporate connectivity** especially in the context of certain parts of the institutional markets — notably leveraged investors — under pressure from balance sheet constraints (including B3 leverage). Thus, we expect greater focus on wallet share from traditional corporate customer, with banks increasingly leveraging such relationships via cash management, corporate banking and transaction banking franchise. In Europe, disintermediation remains a powerful secular trend.

Key Restructuring Highlights:

- **Barclays**: Exit Quadrant B3 RWAs of £79bn (end-2012) have been reduced to £42bn with a further targeted reduction to £36bn by end-2015. This includes pre-B3 rates business as well as corporate/monoline derivatives.
- **CS**: Rates-related RWA reduction from US\$16bn to US\$9bn and leverage exposure from US\$141bn to US\$81bn. This includes a reduction in capital-intensive structured rates activity as part of the business model migration to simplified, primarily cleared products. This follows an earlier scaling back of CS's ambitions in FX and Commodities.

- **Deutsche Bank** recently announced that it is significantly scaling back its commodities business including exiting the dedicated trading desks for energy, agriculture, base metals and dry bulk. The business will now focus on financial derivatives and precious metals to be integrated into Deutsche Bank's Fixed Income and Currencies platform.
- **UBS:** FICC-related RWA reduction from SFr110bn to SFr30bn, funded assets reduction from SFr330bn to SFr70bn as well as a SFr300bn reduction in the derivatives book — focused on the Credit and Rates business.
- **RBS:** Reduction in Wholesale from 20% of Group RWAs to 15% in steady state. This is based on £50bn reduction in B3 RWAs to £45bn in steady state with targeted revenues of £2bn vs 2013 level of £3.3bn. RBS also recently announced the disposal of its structured retail investor products and equity derivatives businesses to BNP Paribas.

Figure 23. FICC Market Shares – By Underlying Revenue, 2006-2013

	2006	2007	1H08	2009	2010	2011	2012	2013	2013 vs. 2006
JP Morgan	8.8%	8.5%	7.2%	9.4%	10.2%	12.8%	11.6%	13.3%	451 bps
Deutsche Bank	8.3%	9.7%	11.8%	8.5%	10.5%	11.8%	10.5%	9.6%	133 bps
Bank of America	10.0%	10.0%	8.8%	9.1%	9.8%	8.3%	9.6%	9.5%	-54 bps
Goldman Sachs	9.6%	11.5%	12.3%	13.9%	10.5%	8.5%	9.0%	9.0%	-61 bps
Barclays	10.3%	14.7%	15.0%	11.1%	10.2%	9.7%	10.0%	8.9%	-136 bps
Credit Suisse	5.6%	5.4%	4.1%	5.2%	5.1%	4.6%	5.8%	5.7%	12 bps
HSBC	3.6%	3.2%	4.8%	4.7%	4.7%	4.7%	5.0%	5.7%	208 bps
RBS	10.9%	9.7%	5.4%	7.4%	6.4%	5.9%	6.0%	5.3%	-562 bps
BNP Paribas	2.8%	3.5%	3.6%	6.2%	5.6%	6.3%	5.1%	4.8%	204 bps
Morgan Stanley	6.8%	6.7%	5.9%	4.8%	5.7%	6.3%	5.1%	4.2%	-260 bps
Nomura	3.5%	2.6%	2.7%	1.5%	2.2%	3.2%	3.9%	4.2%	67 bps
Societe Generale	2.1%	1.9%	2.9%	2.9%	2.5%	2.7%	3.1%	3.0%	94 bps
Credit Agricole	2.3%	2.0%	1.5%	1.8%	1.7%	1.8%	1.8%	1.8%	-48 bps
UBS	4.8%	2.4%	1.6%	1.5%	3.7%	2.5%	1.7%	1.7%	-308 bps
US	45.9%	44.8%	46.5%	49.2%	47.5%	46.9%	47.1%	49.3%	336 bps
Europe	50.6%	52.6%	50.8%	49.3%	50.3%	49.9%	49.0%	46.6%	-403 bps
Top 5	47.4%	47.9%	52.3%	52.9%	52.3%	52.4%	52.5%	54.6%	729 bps
Rest	52.6%	52.1%	47.7%	47.1%	47.7%	47.6%	47.5%	45.4%	-729 bps

Source: Company Reports, Citi Research

Note: JPM adjusted for tax equivalent adjustment component; JPM, BoA, Barclays & Nomura pro-forma for acquisitions of Bear Stearns, Merrill Lynch & Lehman Bros respectively

Figure 24. Equities Sales & Trading Market Shares – By Underlying Revenue, 2006-2013

	2006	2007	1H08	2009	2010	2011	2012	2013	2013 vs. 2006
Goldman Sachs	15.9%	16.2%	16.7%	18.0%	14.6%	15.8%	16.9%	13.5%	-237 bps
Morgan Stanley	9.4%	10.0%	13.1%	7.9%	8.9%	12.1%	12.5%	12.5%	310 bps
Credit Suisse	7.0%	7.6%	8.3%	10.3%	10.3%	9.3%	9.8%	9.9%	292 bps
JP Morgan	8.0%	6.7%	4.0%	7.2%	8.3%	8.8%	9.5%	9.0%	102 bps
UBS	9.3%	8.3%	8.8%	6.8%	7.6%	8.5%	6.9%	8.1%	-122 bps
Bank of America	10.0%	9.9%	10.2%	7.3%	7.5%	7.2%	7.0%	8.0%	-207 bps
Barclays	5.6%	5.5%	5.8%	5.0%	5.7%	5.7%	7.4%	7.9%	228 bps
Deutsche Bank	7.5%	7.3%	6.0%	6.1%	7.4%	6.1%	6.3%	6.8%	-68 bps
Societe Generale	5.7%	5.3%	5.1%	6.9%	5.9%	5.8%	5.2%	6.2%	53 bps
Nomura	3.8%	5.1%	3.6%	4.8%	4.9%	4.7%	4.5%	4.9%	109 bps
BNP Paribas	4.5%	4.4%	4.1%	4.1%	5.4%	5.6%	4.5%	4.5%	3 bps
HSBC	1.2%	1.2%	1.9%	1.0%	1.4%	1.9%	1.5%	2.1%	85 bps
Credit Agricole	3.7%	3.7%	3.0%	3.2%	3.6%	3.8%	2.7%	1.0%	-267 bps
RBS	2.7%	2.7%	2.8%	3.4%	1.9%	-%	-%	-%	-270 bps
US	49.1%	48.9%	50.7%	48.5%	45.9%	48.6%	51.2%	48.6%	-43 bps
Europe	47.1%	46.1%	45.7%	46.7%	49.2%	46.7%	44.3%	46.5%	-67 bps
Top 5	49.5%	48.9%	50.9%	50.2%	49.7%	54.4%	55.6%	52.9%	345 bps
Rest	50.5%	51.1%	49.1%	49.8%	50.3%	45.6%	44.4%	47.1%	-345 bps

Source: Company Reports, Citi Research

Note: JPM, BoA, Barclays & Nomura pro-forma for acquisitions of Bear Sterns, Merrill Lynch & Lehman Bros respectively

Figure 25. Primary Market Shares – By Underlying Revenue, 2006-2013

Pro Forma	2006	2007	1H08	2009	2010	2011	2012	2013	2013 vs. 2006
Bank of America	15%	14%	16%	14%	14%	15%	15%	15%	89 bps
JP Morgan	15%	15%	14%	18%	16%	16%	15%	15%	18 bps
Goldman Sachs	13%	14%	14%	12%	12%	12%	13%	14%	192 bps
Morgan Stanley	9%	10%	9%	11%	11%	12%	11%	11%	112 bps
Deutsche Bank	8%	9%	8%	8%	8%	8%	9%	9%	75 bps
Credit Suisse	10%	8%	7%	7%	10%	9%	9%	9%	-95 bps
Barclays	4%	4%	7%	8%	9%	9%	9%	8%	408 bps
UBS	10%	11%	9%	8%	7%	7%	7%	6%	-371 bps
Nomura	5%	4%	5%	3%	3%	3%	3%	3%	-216 bps
US	63%	63%	64%	66%	63%	64%	64%	65%	197 bps
Europe	32%	32%	31%	31%	34%	34%	34%	32%	18 bps
Top 5	63%	63%	64%	66%	63%	64%	64%	65%	197 bps
Rest	37%	37%	36%	34%	37%	36%	36%	35%	-197 bps

Source: Company Reports, Citi Research

Note: JPM, BoA, Barclays & Nomura pro-forma for acquisitions of Bear Sterns, Merrill Lynch & Lehman Bros respectively

Comparative Valuation Metrics

Figure 26. Wholesale Banks – Valuation Metrics

Company	Rec	RIC	Ccy	Share Price			P/E		P/B	P/tB	RoE	RoE	DY	Performance (Absolute)				M Cap \$bn
				Now	Target	+/-%	2014E	2015E	2014E	2014E	2014E	2015E	2014E	YTD	1m	3m	12m	
Nomura	Buy	8604.T	JPY	662	1,000	+51%	11.7x	12.7x	1.0x	1.0x	8%	8%	2.6%	-18%	-4%	-18%	+15%	24
RBS	Sell-H	RBS.L	GBP	3.08	2.70	-12%	16.0x	11.9x	0.7x	0.9x	4%	6%	0.0%	-9%	-6%	-9%	+12%	58
Morgan Stanley	Neutral	MS.N	USD	30.9	35.0	+13%	12.9x	11.2x	0.9x	1.1x	7%	8%	1.3%	-1%	+0%	-1%	+41%	61
Bank of America	Buy	BAC.N	USD	17.0	19.0	+12%	15.4x	10.3x	0.8x	1.1x	5%	7%	0.9%	+9%	+3%	+9%	+39%	179
HSBC	Neutral	HSBA.L	GBP	6.10	6.85	+12%	11.3x	10.3x	1.0x	1.2x	9%	10%	4.8%	-8%	-3%	-8%	-13%	191
UBS	Buy	UBSN.VX	CHF	18.2	22.0	+21%	12.7x	9.8x	1.4x	1.6x	11%	13%	2.7%	+8%	-3%	+8%	+25%	79
JPMorgan	Buy	JPM.N	USD	60.0	72.0	+20%	10.5x	9.7x	1.1x	1.3x	10%	11%	2.7%	+3%	+6%	+3%	+27%	227
Goldman Sachs	Neutral	GS.N	USD	162.3	195.0	+20%	10.8x	9.7x	1.0x	1.1x	10%	10%	1.4%	-8%	-2%	-8%	+10%	73
BNP Paribas	Buy	BNPP.PA	EUR	56.1	71.0	+27%	10.7x	8.6x	0.8x	1.0x	8%	9%	4.2%	-1%	-6%	-1%	+40%	96
Credit Suisse	Buy	CSGN.VX	CHF	28.5	34.0	+19%	10.3x	8.1x	1.0x	1.2x	10%	12%	2.6%	+5%	+3%	+5%	+17%	51
Credit Ag	Buy	CAGR.PA	EUR	11.5	15.0	+31%	9.3x	7.7x	0.7x	1.1x	7%	9%	3.8%	+23%	-1%	+23%	+78%	39
Soc Gen	Buy	SOGN.PA	EUR	44.7	59.0	+32%	10.3x	7.7x	0.7x	0.9x	7%	9%	3.9%	+6%	-8%	+6%	+75%	49
Barclays	Buy	BARC.L	GBP	2.32	3.45	+48%	7.0x	5.9x	0.6x	0.7x	9%	10%	5.4%	-15%	-8%	-15%	-14%	63
Deutsche Bank	Buy	DBKGn.DE	EUR	32.4	45.0	+39%	5.6x	4.7x	0.6x	0.7x	10%	12%	2.3%	-7%	-8%	-7%	+6%	45
Large-Caps							11.7x	9.6x	0.9x	1.2x	8%	10%	2.8%	+0%	-1%	+0%	+23%	1192

Note: Prices as at 28 March, 2014

Source: dataCentral, Citi Research

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of BNP Paribas SA Citigroup Global Markets Limited is currently mandated as sole global co-ordinator in relation to the recently announced re-IPO of BNP Paribas SA's polish subsidiary, BNP Paribas Bank Polska.

Interbank Offered Rates-Related Litigation and Other Matters: Government agencies in the U.S., including the Department of Justice, the Commodity Futures Trading Commission and the Securities and Exchange Commission, as well as agencies in other jurisdictions, including the European Commission, the U.K. Financial Services Authority, the Japanese Financial Services Agency (JFSA) and the Canadian Competition Bureau, are conducting investigations or making inquiries regarding submissions made by panel banks to bodies that publish various interbank offered rates. As members of a number of such panels, Citigroup subsidiaries have received requests for information and documents. Citigroup is cooperating with the investigations and inquiries and is responding to the requests. Consequently Citi Research is not commenting on the quantum or likelihood of any potential LIBOR related claims or settlements. Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Barclays PLC

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Goldman Sachs Group Inc

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Societe Generale

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Morgan Stanley

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Credit Suisse Group AG

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Royal Bank of Scotland Group PLC

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of HSBC Holdings PLC

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of JPMorgan Chase & Co

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Bank of America Corp

Nicholas Herman, Associate, holds a long position in the securities of Bank of America Corp.

A member of the household of Keith Horowitz, CFA, Analyst, holds a long position in the securities of JP Morgan Chase & Co.

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Goldman Sachs Group, Inc., Bank of America Corp. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Nomura Holdings, BNP Paribas SA, Barclays PLC, Goldman Sachs Group, Inc., Societe Generale, Morgan Stanley, Credit Suisse, Royal Bank of Scotland Group PLC, HSBC Holdings PLC, JP Morgan Chase & Co, Bank of America Corp, Credit Agricole SA.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Nomura Holdings, UBS, Deutsche Bank, BNP Paribas SA, Barclays PLC, Goldman Sachs Group, Inc., Societe Generale, Morgan Stanley, Credit Suisse, Royal Bank of Scotland Group PLC, HSBC Holdings PLC, JP Morgan Chase & Co, Bank of America Corp, Credit Agricole SA.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from UBS, BNP Paribas SA, Goldman Sachs Group, Inc., Royal Bank of Scotland Group PLC, HSBC Holdings PLC.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Nomura Holdings, UBS, Deutsche Bank, BNP Paribas SA, Barclays PLC, Goldman Sachs Group, Inc., Societe Generale, Morgan Stanley, Credit Suisse, Royal Bank of Scotland Group PLC, HSBC Holdings PLC, JP Morgan Chase & Co, Bank of America Corp, Credit Agricole SA in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): HSBC Holdings PLC, Barclays PLC, Royal Bank of Scotland Group PLC, Nomura Holdings, UBS, Deutsche Bank, BNP Paribas SA, Goldman Sachs Group, Inc., Societe Generale, Morgan Stanley, Credit Suisse, JP Morgan Chase & Co, Bank of America Corp, Credit Agricole SA.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Nomura Holdings, UBS, Deutsche Bank, BNP Paribas SA, Barclays PLC, Goldman Sachs Group, Inc., Societe Generale, Morgan Stanley, Credit Suisse, Royal Bank of Scotland Group PLC, HSBC Holdings PLC, JP Morgan Chase & Co, Bank of America Corp, Credit Agricole SA.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: Nomura Holdings, UBS, Deutsche Bank, BNP Paribas SA, Barclays PLC, Goldman Sachs Group, Inc., Societe Generale, Morgan Stanley, Credit Suisse, Royal Bank of Scotland Group PLC, HSBC Holdings PLC, JP Morgan Chase & Co, Bank of America Corp, Credit Agricole SA.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

The Firm is a market maker in the publicly traded equity securities of BNP Paribas SA, Barclays PLC, Societe Generale, HSBC Holdings PLC.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Research Equity Ratings Distribution

Data current as of 31 Mar 2014

	12 Month Rating			Relative Rating		
	Buy	Hold	Sell	Buy	Hold	Sell
Citi Research Global Fundamental Coverage	49%	40%	12%	1%	98%	1%
% of companies in each rating category that are investment banking clients	55%	53%	45%	58%	53%	42%

Guide to Citi Research Fundamental Research Investment Ratings:

Citi Research stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

Risk rating takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned.

Investment Ratings: Citi Research investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect with the approval of Citi Research management not to assign a target price and, thus, not derive an ETR. Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and / or trading in the company's securities (e.g. trading suspension). As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. To satisfy regulatory requirements, we correspond Under Review and Neutral to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation.

Relative three-month ratings: Citi Research may also assign a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the geographic and industry sector over a 3 month period. The relative call may highlight a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) will indicate the most and least preferred stocks in the universe of stocks under consideration, explaining the basis for this short-term view. This three-month view may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls correspond to a buy recommendation and least preferred calls correspond to a sell recommendation. Any stock not assigned to a most preferred or least preferred call is considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we correspond NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we do not consider NRR to be a recommendation.

Prior to October 8, 2011, the firm's stock recommendation system included a risk rating and an investment rating. **Risk ratings**, which took into account both price volatility and fundamental criteria, were: Low (L), Medium (M), High (H), and Speculative (S). **Investment Ratings** of Buy, Hold and Sell were a function of the Citi Research expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating. Additionally, analysts could have placed covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" were monitored daily by management and as practically possible, the analyst published a note re-establishing a rating and investment thesis. For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings were: Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return). For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings were: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Ltd	Kinner Lakhani; Nicholas Herman; Andrew Coombs; Ronit Ghose; Azzurra Guelfi; Stefan Nedialkov; Simon Nellis; Florent Nitu; Yafei Tian
Citigroup Global Markets India Private Limited	Rahul Bajaj; Vikas Sharma

Citigroup Global Markets Inc.
Citigroup Global Markets Japan Inc.

Keith Horowitz, CFA
Hironari Nozaki, CFA

OTHER DISCLOSURES

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to UBS, BNP Paribas SA, Barclays PLC, Goldman Sachs Group, Inc., Morgan Stanley, Credit Suisse, Royal Bank of Scotland Group PLC, JP Morgan Chase & Co, Bank of America Corp. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citi-velocity.com.)

Citigroup Global Markets Inc. or its affiliates beneficially owns 2% or more of any class of common equity securities of Goldman Sachs Group, Inc..

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Bell Potter Customers: Bell Potter is making this Product available to its clients pursuant to an agreement with Citigroup Global Markets Australia Pty Limited. Neither Citigroup Global Markets Australia Pty Limited nor any of its affiliates has made any determination as to the suitability of the information provided herein and clients should consult with their Bell Potter financial advisor before making any investment decision.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citigroup Global Markets Australia Pty Limited. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is

regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised by the PRA and regulated by the FCA and the PRA. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294

Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA. This material may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the PRA nor regulated by the FCA and the PRA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is authorised by the PRA and regulated by the FCA and the PRA.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/epublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. Citi Research generally disseminates its research to the Firm's global institutional and retail clients via both proprietary (e.g., Citi Velocity and Citi Personal Wealth Management) and non-proprietary electronic distribution platforms. Certain research may be disseminated only via Citi's proprietary distribution platforms; however such research will not contain changes to earnings forecasts, target price, investment or risk rating or investment thesis or be otherwise inconsistent with the author's previously published research. Certain research is made available only to institutional investors to satisfy regulatory requirements. Individual Citi Research analysts may also opt to circulate published research to one or more clients by email; such email distribution is discretionary and is done only after the research has been disseminated.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Thomson Reuters.

© 2014 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST